October 19 at 8:30 am PDT / 11:30 am EDT
Cancer didn't quit during the pandemic, but neither did cancer innovation. We even saw approaches first pioneered in cancer now deployed against COVID-19. Genomic and multi-omics data are transforming cancer research. Immunotherapy remains a significant area of major investment and of promise for patients. What are the most exciting oncology innovations we can look forward to in the near term? What are the greatest remaining unmet patient needs? And how are the cancer research and treatment communities addressing inequities in research and care across racial, ethnic, and geographic lines?
Founder & Editor, Timmerman Report
Michael and Lori Milken Dean of Public Health, Milken Institute School of Public Health, The George Washington University
Charles (Chuck) Ryan
President and CEO, Prostate Cancer Foundation
CEO, Kite, a Gilead Company